Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills

Research output: Contribution to journalShort survey

7 Scopus citations

Abstract

In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

Original languageEnglish (US)
Pages (from-to)7-9
Number of pages3
JournalCancer Cell
Volume26
Issue number1
DOIs
StatePublished - Jul 14 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors'. Together they form a unique fingerprint.

Cite this